根据《中华人民共和国药品管理法》《药品生产监督管理办法》《药品检查管理办法（试行）》《药品生产质量管理规范符合性检查工作程序》有关规定及 要求，我局对华东医药（西安）博华制药有限公司等7家药品生产企业进行药品生产质量管理规范符合性检查和审核，经现场检查并综合评定，现将检查结 果通告如下： | 受托方： 榆林利君 制药有限 | | | | | | --- | --- | --- | --- | --- | | 公司 | | | | | | 西安力邦 | 西安市未央 | | 2025年9 月16 | | | 制药有限 | 区六村堡工 | 原料药：右泛醇（二车间、三车间、净化二车间，右泛醇生产线） | 日-2025 | 符 | | 公司 | 业园丰产路 42号 | | 年9月19 | 合 | | | | | 日 | | | 西安力邦 | 西安市高新 | | 2025年9 月22 | | | 制药有限 | 区科技一路 | 前列地尔注射液（一车间，2线）、小容量注射剂（一车间，1线、2线） | 日-2025 | 符 | | 公司 | 22号 | | 年9月24 | 合 | | | | | 日 | | | | 辽宁省新民 ...

Core Viewpoint - Jia Ying Pharmaceutical is a well-known enterprise in the traditional Chinese medicine sector, focusing on the research and production of traditional Chinese medicine with unique processing technology [1] Group 1: Business Performance - For Q3 2025, Jia Ying Pharmaceutical reported revenue of 293 million yuan, ranking 62nd among 69 companies in the industry, with the industry leader Baiyunshan generating 61.606 billion yuan [2] - The company's net profit for the same period was 21.7943 million yuan, placing it 50th in the industry, while the top performer, Yunnan Baiyao, achieved a net profit of 4.789 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Jia Ying Pharmaceutical's debt-to-asset ratio was 8.48%, significantly lower than the industry average of 32.81%, indicating strong solvency [3] - The company's gross profit margin stood at 56.41%, higher than the industry average of 52.44%, reflecting a robust profit potential for its products [3] Group 3: Executive Compensation - The chairman, Li Neng, received a salary of 253,300 yuan in 2024, while the general manager, You Yongping, earned 370,000 yuan [4] Group 4: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.91% to 24,500, with the average number of circulating A-shares held per shareholder increasing by 0.92% to 20,700 [5]

Core Viewpoint - The Heilongjiang Provincial Drug Administration announced the results of the GMP compliance inspections for 16 pharmaceutical companies, confirming their adherence to the 2010 revised Good Manufacturing Practice standards [3]. Group 1: Compliance Inspection Results - Heilongjiang Sanlian Pharmaceutical Co., Ltd. was inspected for its small-volume injection production line, specifically for anti-tumor drugs, and found compliant [3]. - Harbin Pharmaceutical Group's second factory was inspected for its granule and oral liquid production lines, confirming compliance [3]. - Heilongjiang Huabei Pharmaceutical Co., Ltd. was inspected for its solid dosage forms and traditional Chinese medicine extraction processes, and was found compliant [3]. Group 2: Inspection Details - The inspections were conducted between April and May 2025, with specific dates for each company listed [3]. - The inspection covered various production lines, including small-volume injections, oral liquids, and traditional Chinese medicine extracts [3]. - The results indicate a focus on ensuring quality and compliance within the pharmaceutical manufacturing sector in Heilongjiang Province [3].

Core Viewpoint - The announcement from the Shanxi Provincial Drug Administration details the results of GMP compliance inspections for 14 pharmaceutical manufacturing companies, indicating their adherence to national drug production standards [2]. Group 1: Inspection Results - The inspection results include companies such as China National Pharmaceutical Group Weichida Pharmaceutical Co., Ltd., which was inspected for hard capsule production of penicillin oral preparations [3]. - Other companies listed include Shanxi Huida Pharmaceutical Co., Ltd. and Shanxi Zhongyuan Pharmaceutical Co., Ltd., with various products ranging from oral solutions to traditional Chinese medicine pieces being evaluated for compliance [3][4]. - The inspections were conducted between January 16 and March 31, 2025, with all companies listed achieving compliance [3][4]. Group 2: Compliance Details - The compliance checks were based on the Drug Administration Law of the People's Republic of China and related regulations, ensuring that the inspected companies meet the required quality management standards [2]. - Specific products inspected include oral solutions, hard capsules, and raw materials, with detailed addresses and production lines provided for each company [3][4]. - The results signify a commitment to maintaining high standards in pharmaceutical production within the region, which is crucial for public health and safety [2].

General Information - Chongqing Pharscin Pharmaceutical Co., Ltd. was established as a joint-stock company in accordance with the Company Law of the People's Republic of China [2] - The company was registered with the Chongqing Market Supervision Administration and obtained its business license on September 22, 2017, with a registered capital of RMB 417.596314 million [2][3] - The company issued 40.06 million shares to the public and was listed on the Shenzhen Stock Exchange on October 20, 2017 [2][3] Company Structure - The company is a permanent joint-stock company, with the chairman serving as the legal representative [3] - The legal representative's civil activities conducted on behalf of the company will have legal consequences for the company [3] - Shareholders are liable for the company's debts only to the extent of their subscribed shares, while the company is liable for its debts with all its assets [3] Management and Governance - Senior management includes the general manager, deputy general managers, financial officer, and board secretary [4] - The company has established a party organization in accordance with the Communist Party of China regulations, which plays a leading role in governance [4] Business Objectives and Scope - The company's business objective is to promote national medicine and provide quality healthcare products [4] - The business scope includes the production of various pharmaceutical forms, including injections, tablets, and traditional Chinese medicine, as well as related consulting and technology transfer services [4][5] Share Issuance and Capital Management - The company issues shares in the form of stocks, adhering to principles of openness, fairness, and justice [6] - The total number of shares issued at the establishment was 300 million, with a par value of RMB 1 per share [6] - The company has a total of 417.596314 million shares issued, all of which are ordinary shares [6] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and participation in company governance [12] - Shareholders must comply with laws and the company's articles of association, and they are liable for their subscribed capital [40] - The company has provisions for shareholders to request the convening of a general meeting under certain conditions [52][57] Corporate Governance and Decision-Making - The general meeting of shareholders is the company's authority, responsible for electing directors and approving major corporate actions [46] - The company must hold an annual general meeting within six months after the end of the fiscal year [51] - Decisions regarding significant transactions and capital changes require shareholder approval [47][50] Financial Management and Investment - The company is required to disclose financial information and adhere to regulations regarding financial assistance and investments [21][49] - The company can engage in financial investments within approved limits and must disclose significant financial activities [48][49]